MedTrace Logo

Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

NCT07342309 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7933

Last updated 2026-02-10

No results posted yet for this study

Summary

This study aims to address the following key objectives in patients with HER2-altered mBC:

Primary objectives

* Estimate the prevalence of human epidermal growth factor receptor 2 positive (HER2+), human epidermal growth factor receptor 2 (HER2) mutation, cooccurrence of HER2+ and HER2 mutation among adult patients with metastatic breast cancer (mBC)
* Among mBC patients with HER2+ and HER2 mutation, describe the following:

* Baseline demographic and clinical characteristics
* Treatment patterns during follow-up including 1L through fifth-line (5L) settings
* Real-world overall survival (rwOS) for 1L through 5L

Secondary objectives

\- Among mBC patients with HER2+ and HER2 mutation, examine the following (as permissible in the study data):

* Real-world progression-free survival (rwPFS)
* Real-world time to discontinuation (rwTTD)
* Real-world time to next treatment (rwTTNT)
* Real-world overall response rate (rwORR)

Conditions

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07342309 on ClinicalTrials.gov